Transthyretin Amyloid Cardiomyopathy Clinical Trial
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Summary
The purpose of this study is to:
Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
Characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting
Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation
Eligibility Criteria
Inclusion Criteria:
Diagnosis of ATTR amyloidosis or documented known disease-causing TTR mutation for the cohort of pre-symptomatic carriers
Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
Exclusion Criteria:
Current enrollment in a clinical trial for any investigational agent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 12 Locations for this study
La Jolla California, 92037, United States
Los Angeles California, 90095, United States
Jacksonville Florida, 32224, United States
Iowa City Iowa, 52242, United States
Kansas City Kansas, 66160, United States
Baltimore Maryland, 21224, United States
Boston Massachusetts, 02127, United States
New York New York, 10034, United States
Durham North Carolina, 27710, United States
Columbus Ohio, 43210, United States
Philadelphia Pennsylvania, 19104, United States
Austin Texas, 78756, United States
Salvador , , Brazil
Arhus , , Denmark
Copenhagen , , Denmark
Bordeaux , , France
Bron , , France
Hanover , , Germany
Jerusalem , , Israel
Ramat Gan , , Israel
Milan , , Italy
Roma , , Italy
Groningen , , Netherlands
Lisbon , , Portugal
Barcelona , , Spain
Palma , , Spain
How clear is this clinincal trial information?